Sugi Predict

Sugi Predict / Compounds / SCHEMBL690412

SCHEMBL690412

SCHEMBL690412

CC(=O)c1cc(F)c(Cl)cc1F

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.46
▸ APEX1 P27695 1/20 0.46
▸ HPGD P15428 4/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ GPR27 Q9NS67 1/20 0.41
▸ MAOB P27338 2/20 0.41
▸ MAOA P21397 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ TSHR P16473 3/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ MAPT P10636 2/20 0.40
▸ KEAP1 Q14145 1/20 0.38
▸ NFE2L2 Q16236 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29997409 1.00 POLB (0.46) POLBAPEX1HPGDALDH1A1GPR27
SCHEMBL17071867 0.89 POLB (0.43) POLBAPEX1HPGDMAOBMAOA
SCHEMBL15757221 0.87 POLB (0.46) POLBAPEX1HPGDMAOBMAOA
SCHEMBL2630704 0.87 POLB (0.46) POLBAPEX1HPGDGPR27MAOB
SCHEMBL6561685 0.86 TSHR (0.46) ALDH1A1MAOBMAOASMN1; SMN2TSHR
SCHEMBL3621616 0.84 POLB (0.56) POLBAPEX1HPGDSMN1; SMN2TSHR
SCHEMBL2075295 0.83 KDM4E (0.42) POLBAPEX1HPGDALDH1A1MAOB
SCHEMBL4158847 0.83 HTT (0.46) POLBAPEX1HPGDALDH1A1MAOB
SCHEMBL9618645 0.83 HSP90AA1 (0.40) POLBAPEX1HPGDALDH1A1MAOB
SCHEMBL29495384 0.83 HTT (0.46) POLBAPEX1HPGDALDH1A1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1990012780-A1 INTERMEDIATES FOR THE PRODUCTION OF 2,4,5-TRIFLUORBENZOYL FLUORIDE MALLINCKRODT, INC. (US) 1990-11-01 — — WO claimed
US-12404253-B2 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 ASTRAZENECA AB (SE) 2025-09-02 — — US disclosed
WO-2025077773-A1 NOVEL TYPE I TOPOISOMERASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊维康医药有限责任公司 2025-04-17 — — WO disclosed
US-20240383866-A1 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 ASTRAZENECA AB (SE) 2024-11-21 — — US disclosed
US-20240199558-A1 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 ASTRAZENECA AB (SE) 2024-06-20 — — US disclosed
WO-2024083933-A1 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX 3CR1 ASTRAZENECA AB (SE) 2024-04-25 — — WO disclosed
US-20240018108-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2024-01-18 — — US disclosed
US-20240018108-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2024-01-18 — — US disclosed
US-20240018108-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2024-01-18 — — US disclosed
CN-115361948-A Methods and compositions for inhibiting dihydroorotate dehydrogenase 俄亥俄州国家创新基金会 2022-11-18 — — CN disclosed
EP-1597248-A2 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2005-11-23 — — EP disclosed
WO-2004073606-A2 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2004-09-02 — — WO disclosed
US-6552062-B1 For therapy of central nervous system disorders; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and obesity VERNALIS RESEARCH LIMITED (GB) 2003-04-22 — — US disclosed
EP-1129078-A2 INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY VERNALIS RESEARCH LIMITED (GB) 2001-09-05 — — EP disclosed
US-6150303-A Substituted 3-phenylisoxazolines BASF AKTIENGESELLSCHAFT (DE) 2000-11-21 — — US disclosed
WO-2000012481-A2 INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY________________ VERNALIS RESEARCH LIMITED (GB) 2000-03-09 — — WO disclosed
EP-0652876-A1 HERBICIDAL TRIAZINONES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1995-05-17 — — EP disclosed
WO-1994003454-A1 HERBICIDAL TRIAZINONES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1994-02-17 — — WO disclosed
US-4996355-A Novel intermediates for the production of 2,4,5-trifluorobenzoyl fluoride MALLINCKRODT, INC. (US) 1991-02-26 — — US disclosed
WO-1990012780-A1 INTERMEDIATES FOR THE PRODUCTION OF 2,4,5-TRIFLUORBENZOYL FLUORIDE MALLINCKRODT, INC. (US) 1990-11-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199558-A1 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 CX3CR1, CCR2, CCR5 POLB 4442/4885APEX1 3567/4885HPGD 1142/4885
US-20240383866-A1 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 CX3CR1, CCR2, CCR5 POLB 4442/4885APEX1 3567/4885HPGD 1142/4885
US-12404253-B2 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 CX3CR1, CCR2, CCR5 POLB 4442/4885APEX1 3567/4885HPGD 1142/4885
US-20240018108-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DLD, FAH POLB 1706/4885APEX1 1454/4885HPGD 330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.